Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-22,105
Closed -$1.18M 52
2024
Q3
$1.18M Sell
22,105
-103,690
-82% -$5.15M 0.43% 37
2024
Q2
$5.27M Hold
125,795
1.95% 17
2024
Q1
$4.51M Hold
125,795
1.63% 22
2023
Q4
$5.21M Buy
125,795
+2,750
+2% +$106K 2.01% 20
2023
Q3
$4.55M Buy
123,045
+49,975
+68% +$2.03M 1.98% 21
2023
Q2
$3.12M Sell
73,070
-245
-0.3% -$11.1K 1.4% 26
2023
Q1
$3.59M Buy
73,315
+1,876
+3% +$90.9K 1.77% 24
2022
Q4
$3.37M Buy
71,439
+1,080
+2% +$48.2K 1.98% 22
2022
Q3
$2.96M Buy
70,359
+2,269
+3% +$106K 1.77% 22
2022
Q2
$4.06M Sell
68,090
-3,900
-5% -$276K 2.19% 18
2022
Q1
$5.72M Sell
71,990
-51,280
-42% -$3.47M 2.25% 14
2021
Q4
$7.65M Buy
+123,270
New +$6.99M 2.76% 7

Other funds holding NEM

Altrafin AG's NEM Position: Q4 2024 in Review

Altrafin AG sold out of Newmont (NEM) in Q4 2024, closing a stake of 22,105 shares — an estimated $1.18M sold.

Altrafin AG first reported a position in NEM in Q4 2021 and held it in 12 quarters. The position peaked at $7.65M in Q4 2021. 1,163 funds tracked by Wall St. Rank hold NEM as of Q4 2024.

  • Altrafin AG reported no remaining Newmont position as of Q4 2024 after selling out during the quarter.
  • Altrafin AG sold 22,105 Newmont shares in Q4 2024, an estimated $1.18M.
  • Altrafin AG first reported a position in Newmont in Q4 2021 and held it in 12 quarters.
  • Altrafin AG's Newmont position peaked at $7.65M in Q4 2021.
  • 1,163 funds tracked by Wall St. Rank held Newmont as of Q4 2024.

Based on Altrafin AG's 13F filing for Q4 2024, filed 17 Feb 2026.